Target Gene/Pathway(薬物標的遺伝子/パスウェイリスト)
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z other
No. | KEGG PATHWAY * On map, Yellow: Drug target, Red: Disease-related |
KEGG GENES * | KEGG DRUG * | DrugBank | 指定難病告示番号 * |
1 | Adipocytokine signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
2 | African trypanosomiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
3 | AGE-RAGE signaling pathway in diabetic complications |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
4 | Allograft rejection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
5 | Alzheimer disease |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
6 | Amoebiasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
7 | Amyotrophic lateral sclerosis (ALS) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
8 | Antifolate resistance |
2件: DHFR, DHFR2 | D00142 | Methotrexate | 33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
D02115 | |||||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
9 | Antigen processing and presentation |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
10 | Apoptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
11 | Asthma |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
12 | C-type lectin receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
13 | cGMP-PKG signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
14 | Chagas disease (American trypanosomiasis) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
15 | Complement and coagulation cascades |
1件: C5AR1 | D11093 | Avacopan | 4件: 43, 44, 222, 223 |
16 | Cytokine-cytokine receptor interaction |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
1件: TNFSF13B | D03068 | Belimumab | 8件: 11, 43, 44, 46, 49, 51, 53, 222 | ||
17 | Dilated cardiomyopathy (DCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
18 | Drug metabolism - other enzymes |
2件: IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | 32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
D05094 | |||||
D05095 | |||||
D05096 | Mycophenolic acid | 34件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
19 | EGFR tyrosine kinase inhibitor resistance |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
20 | Epstein-Barr virus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
21 | Estrogen signaling pathway |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
22 | Fc epsilon RI signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
23 | Fluid shear stress and atherosclerosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
24 | Folate biosynthesis |
2件: DHFR, DHFR2 | D00142 | Methotrexate | 33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
D02115 | |||||
25 | Graft-versus-host disease |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
26 | Hematopoietic cell lineage |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: MS4A1 | D02994 | Rituximab | 42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 | ||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
27 | Hepatitis B |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
28 | Hepatitis C |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
29 | Herpes simplex virus 1 infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
30 | HIF-1 signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
31 | Human cytomegalovirus infection |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
32 | Human immunodeficiency virus 1 infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
33 | Human papillomavirus infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
34 | Human T-cell leukemia virus 1 infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
35 | Hypertrophic cardiomyopathy (HCM) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
36 | IL-17 signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
37 | Inflammatory bowel disease (IBD) |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
38 | Influenza A |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
39 | Insulin resistance |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
40 | Intestinal immune network for IgA production |
1件: TNFSF13B | D03068 | Belimumab | 8件: 11, 43, 44, 46, 49, 51, 53, 222 |
41 | JAK-STAT signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
42 | Legionellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
43 | Leishmaniasis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
44 | Malaria |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
45 | MAPK signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
46 | Metabolic pathways |
2件: DHFR, DHFR2 | D00142 | Methotrexate | 33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
D02115 | |||||
2件: IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | 32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 | ||
D05094 | |||||
D05095 | |||||
D05096 | Mycophenolic acid | 34件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
47 | Morphine addiction |
1件: OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
48 | mTOR signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
49 | Natural killer cell mediated cytotoxicity |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
50 | Necroptosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
51 | Neuroactive ligand-receptor interaction |
1件: C5AR1 | D11093 | Avacopan | 4件: 43, 44, 222, 223 |
1件: NR3C1 | D00407 | Methylprednisolone | 36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 | ||
D00751 | |||||
D00979 | |||||
D05000 | |||||
D05001 | |||||
D05002 | |||||
D00472 | Prednisolone | 38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 | |||
D00980 | |||||
D00981 | |||||
D00982 | |||||
D01239 | |||||
D01998 | |||||
D02156 | |||||
D03301 | |||||
D00473 | Prednisone | 44件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 145, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 | |||
D00385 | Triamcinolone | 18件: 6, 10, 13, 35, 40, 41, 42, 43, 44, 45, 46, 56, 70, 90, 96, 97, 226, 298 | |||
D00983 | |||||
D00984 | |||||
D00985 | |||||
D06216 | |||||
3件: OPRD1, OPRK1, OPRM1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 | ||
D05113 | |||||
52 | NF-kappa B signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
1件: TNFSF13B | D03068 | Belimumab | 8件: 11, 43, 44, 46, 49, 51, 53, 222 | ||
53 | NOD-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
54 | Non-alcoholic fatty liver disease (NAFLD) |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
55 | One carbon pool by folate |
2件: DHFR, DHFR2 | D00142 | Methotrexate | 33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
D02115 | |||||
56 | Osteoclast differentiation |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
57 | Pathogenic Escherichia coli infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
58 | Pathways in cancer |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
59 | Pertussis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
60 | PI3K-Akt signaling pathway |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
61 | Proteoglycans in cancer |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
62 | Purine metabolism |
2件: IMPDH1, IMPDH2 | D00752 | Mycophenolate mofetil | 32件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 85, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
D05094 | |||||
D05095 | |||||
D05096 | Mycophenolic acid | 34件: 2, 11, 13, 14, 19, 20, 28, 35, 36, 42, 43, 45, 49, 51, 53, 60, 62, 65, 66, 84, 85, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 | |||
63 | Rheumatoid arthritis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
1件: TNFSF13B | D03068 | Belimumab | 8件: 11, 43, 44, 46, 49, 51, 53, 222 | ||
64 | RIG-I-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
65 | Shigellosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
66 | Sphingolipid signaling pathway |
1件: OPRD1 | D02095 | Naltrexone | 11件: 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
D05113 | |||||
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
67 | Staphylococcus aureus infection |
1件: C5AR1 | D11093 | Avacopan | 4件: 43, 44, 222, 223 |
68 | Systemic lupus erythematosus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
69 | T cell receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
70 | TGF-beta signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
71 | Th17 cell differentiation |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
72 | TNF signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
73 | Toll-like receptor signaling pathway |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
74 | Toxoplasmosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
75 | Tuberculosis |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
76 | Type I diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
77 | Type II diabetes mellitus |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |
78 | Viral protein interaction with cytokine and cytokine receptor |
1件: IL6R | D02596 | Tocilizumab | 16件: 2, 13, 40, 41, 43, 46, 50, 51, 53, 54, 55, 86, 107, 266, 271, 331 |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 | ||
79 | Yersinia infection |
1件: TNF | D02598 | Infliximab | 23件: 35, 37, 38, 39, 40, 41, 43, 45, 46, 49, 50, 56, 65, 84, 85, 95, 96, 97, 98, 162, 164, 269, 271 |